The Biosensor is a Platform for Multiple Diagnostic Tests
World-first Organic Thin Film Transistor (OTFT) technology
The Biosensor Platform is a small, printable organic strip designed to put the power of accurate, timely diagnosis in the hands of patients and their primary health practitioners.

By altering the detection element (region A) depending on the specific analyte of interest, we have the ability to produce a whole portfolio of non-invasive, real-time, saliva-based diagnostic tests.
Because both the core OTFT sensing element and the mechanism of action remains the same, tests developed from the Biosensor Platform have the potential to be printed at scale, at a low cost.

Our Journey
The story of the Biosensor

RESEARCH BEGINS
Professor Paul Dastoor and University of Newcastle team began research into conducting polymers.
Professor Paul Dastoor and University of Newcastle team began research into conducting polymers.
1997

IP FILED
IP for Organic Thin-Film Transistor (OTFT) technology filed.
IP for Organic Thin-Film Transistor (OTFT) technology filed.
2013

PUBLICATION
“Detection of saliva-range glucose concentrations using organic thin-film transistors”, Applied Physics Letters, 105, 043303 (2014).
“Detection of saliva-range glucose concentrations using organic thin-film transistors”, Applied Physics Letters, 105, 043303 (2014).
2014

IP ACQUIRED
The iQ Group Global acquires OTFT technology for diabetes management and accelerates development into medical device.
The iQ Group Global acquires OTFT technology for diabetes management and accelerates development into medical device.
2016

US PATENT GRANTED
Patent: US 9,766,199B2
Original IP protected to 2033, with more patents to be filed. Ongoing development by original scientific team.
Patent: US 9,766,199B2
Original IP protected to 2033, with more patents to be filed. Ongoing development by original scientific team.
2017

GBS INC.
Leadership team established for GBS Inc.
BIOSENSOR PLATFORM PIPELINE EXTENDED
The iQ Group Global announces extension of research and development of biosensor for additional indications including cancer, allergen and hormone biomarkers.
CHINA PATENT GRANTED
Patent: CN201380022888.2
Leadership team established for GBS Inc.
BIOSENSOR PLATFORM PIPELINE EXTENDED
The iQ Group Global announces extension of research and development of biosensor for additional indications including cancer, allergen and hormone biomarkers.
CHINA PATENT GRANTED
Patent: CN201380022888.2
2018

PUBLICATION
GenomeWeb acknowledges the Saliva Glucose Biosensor as leading the race to the “holy grail” of life sciences.
GenomeWeb acknowledges the Saliva Glucose Biosensor as leading the race to the “holy grail” of life sciences.
2019

FDA REGULATORY SUBMISSION
commences for De Novo classification of the Saliva Glucose Biosensor.
COVID-19 ANTIBODY PROGRAM
Collaboration with Wyss Institute for Biologically Inspired Engineering at Harvard University commences for COVID-19 antibody program.
commences for De Novo classification of the Saliva Glucose Biosensor.
COVID-19 ANTIBODY PROGRAM
Collaboration with Wyss Institute for Biologically Inspired Engineering at Harvard University commences for COVID-19 antibody program.